Lotus Eye Hospital And Institute Ltd carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.57B |
| Enterprise Value | 2.19B |
Lotus Eye Hospital And Institute Ltd currently has 20.80M shares outstanding.
| Shares Outstanding | 20.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Lotus Eye Hospital And Institute Ltd trades at a trailing price-to-earnings ratio of 2,571.81. The price-to-sales ratio is 3.85, and the price-to-book ratio stands at 9.94.
| PE Ratio | 2,571.81 |
| PS Ratio | 3.85 |
| PB Ratio | 9.94 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Lotus Eye Hospital And Institute Ltd trades at an EV/EBITDA multiple of 1,148.95 and an EV/FCF ratio of 898.40. The EV/Sales ratio of 4.07 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,148.95 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.07 |
| EV / EBITDA | 1,148.95 |
| EV / EBIT | 1,148.95 |
| EV / FCF | 898.40 |
Lotus Eye Hospital And Institute Ltd maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.33, indicating elevated leverage, while an interest coverage ratio of -0.43 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.22 |
| Quick Ratio | 0.41 |
| Debt / Equity | 26.33 |
| Debt / EBITDA | -43.20 |
| Interest Coverage | -0.43 |
| Return on Equity (ROE) | 0.29 |
| Return on Assets (ROA) | 0.11 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.19 |
Over the trailing twelve months, Lotus Eye Hospital And Institute Ltd has paid -1.34M in income taxes, reflecting an effective tax rate of 25.35.
| Income Tax | -1.34M |
| Effective Tax Rate | 25.35 |
Lotus Eye Hospital And Institute Ltd's stock has gained approximately 64.68942% over the past 52 weeks. The 50-day moving average sits at 118.46, while the 200-day moving average is 116.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | 64.68942% |
| 50-Day Moving Average | 118.46 |
| 200-Day Moving Average | 116.48 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Lotus Eye Hospital And Institute Ltd generated 537.14M in revenue and converted that into 804,000.00 in net income, yielding earnings per share of 0.04. EBITDA reached -3.66M, while operating income came in at -3.66M.
| Revenue | 537.14M |
| Gross Profit | 261.47M |
| Operating Income | -3.66M |
| Pretax Income | -536,000.00 |
| Net Income | 804,000.00 |
| EBITDA | -3.66M |
| EBIT | -3.66M |
| Earnings Per Share (EPS) | 0.04 |
Lotus Eye Hospital And Institute Ltd holds 38.27M in cash and equivalents against 158.34M in total debt, resulting in a net debt position of 96.21M. Total book value stands at 207.96M, with working capital of 20.31M providing operational flexibility.
| Cash & Cash Equivalents | 38.27M |
| Total Debt | 158.34M |
| Net Debt | 96.21M |
| Equity (Book Value) | 207.96M |
| Book Value Per Share | 10.19 |
| Working Capital | 20.31M |
Lotus Eye Hospital And Institute Ltd operates with a gross margin of 48.68, reflecting its pricing power and cost economics. The operating margin of -0.68 and net profit margin of 0.15 provide insight into operational efficiency.
| Gross Margin | 48.68 |
| Operating Margin | -0.68 |
| Pretax Margin | -0.10 |
| Profit Margin | 0.15 |
| EBITDA Margin | -0.68 |
Lotus Eye Hospital And Institute Ltd posts an Altman Z-Score of 6.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.19 |